Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

July 31, 2024

Rallybio co-founder joins another CT bioscience company board

Contributed Rallybio co-founders Martin Mackay, Ph.D., left, and Dr. Stephen Uden.

The co-founder of New Haven-based biotech Rallybio, who last week announced plans to resign as executive chairman at the end of the year, has been appointed to the board of another biotech firm in Stamford.

SpringWorks Therapeutics Inc., a commercial-stage biopharmaceutical company focused on cancer and severe rare diseases based at 100 Washington Blvd. in Stamford, announced Monday it has appointed Martin Mackay, to its board of directors. 

Mackay is a co-founder of Rallybio, based at 234 Church St., in New Haven. The privately held company was incorporated in January 2018 as an early-stage biotechnology company developing therapies for patients with severe and rare diseases.

In an 8-K filing with the Securities and Exchange Commission last week, Rallybio said Mackay informed its board that “he will resign his executive chairman role and his employment with Rallybio, effective Dec. 31, 2024.” 

After terminating his employment, Mackay will, however, remain on the board and serve as its chairman, the company said.

When Rallybio was founded, Mackay served as chief executive officer. He was succeeded as CEO on Aug. 1, 2023, by Dr. Stephen Uden, also a co-founder, who had been the company’s president and COO.

When Mackay left the CEO post, he became executive chairman of the board but remained a full-time employee and actively involved in the company, with a “focus on company strategy, investor relations and related activities,” the company said.

Rallybio said last week it expects Mackay to sign a consulting agreement with the company on Jan. 1, 2025. The agreement will allow Mackay to serve as a consultant to Rallybio until Jan. 1, 2026, though the consulting period could be extended upon mutual agreement or terminated by either party with 60 days’ notice.

Before co-founding Rallybio, Mackay had served as executive vice president, head of research and development, at Alexion from 2013-17. 

He has more than 30 years of pharmaceutical and biotech R&D experience, which also includes leadership roles at Pfizer and AstraZeneca.

In addition to Rallybio and SpringWorks, Mackay also serves on the boards of Charles River Laboratories and Novo Nordisk.

Sign up for Enews

0 Comments

Order a PDF